Company Overview
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -32.16% |
| 6 Months: | +40.12% |
| 3 Months: | +2.27% |
| 1 Month: | -2.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 71.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GUTS Fractyl Health, Inc. PHARMA | 0.69 | -0.76 | $109.83M | 0.00% | -93.93% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.00K | 72.00K | 36.00K | 33.00K | 43.00K | 14.00K | - | - | - | - | - |
| Gross Profit | 2.00K | 25.00K | 11.00K | 14.00K | 19.00K | 7.00K | - | - | - | - | - |
| Operating Income | -12.11M | -11.88M | -13.87M | -21.54M | -22.98M | -23.79M | -24.76M | -26.08M | -22.69M | -20.82M | -19.10M |
| Net Income | -11.93M | -30.23M | -15.75M | -3.32M | -17.23M | -23.17M | -23.73M | -27.89M | -45.60M | 9.22M | -25.54M |
| Diluted EPS | -7.87 | -16.62 | -9.61 | -0.17 | -0.36 | -0.48 | -0.49 | -0.57 | -0.71 | 0.06 | -0.16 |
| R&D Expense | 9.35M | 9.14M | 9.38M | 14.42M | 16.76M | 19.00M | 19.43M | 21.15M | 17.46M | 15.60M | 13.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 120.00K | 93.00K | 0 |
| Gross Profit | 43.00K | 43.00K | - |
| Operating Income | -50.84M | -93.53M | -96.82M |
| Net Income | -77.09M | -68.69M | -140.95M |
| Diluted EPS | -45.29 | -1.62 | -1.86 |
| R&D Expense | 38.04M | 70.47M | 74.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 60.96M | 76.21M | 108.08M | 121.40M |
| Current Assets | - | 51.63M | 35.65M | 71.76M | 87.58M |
| Cash & Equivalents | - | 49.27M | 33.21M | 67.46M | 81.54M |
| Inventory | - | 0 | 73.00K | 73.00K | 0 |
| Receivables | - | 0 | 22.00K | 0 | - |
| Total Liabilities | - | 313.27M | 401.27M | 79.65M | 111.94M |
| Current Liabilities | - | 7.31M | 11.19M | 19.77M | 18.33M |
| Long Term Debt | - | 17.76M | 55.15M | 30.16M | 30.59M |
| Total Debt | - | 19.48M | 86.39M | 62.50M | 61.65M |
| Total Equity | - | -252.32M | -325.06M | 28.42M | 9.46M |
| Shares Outstanding | - | 47.55M | 47.90M | 48.76M | 153.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -42.82M | -65.52M | -90.33M |
| Investing Cash Flow | -359.00K | -1.76M | -557.00K |
| Financing Cash Flow | 27.44M | 101.23M | 104.96M |
| Capital Expenditure | -359.00K | -1.76M | -557.00K |
| Free Cash Flow | -43.18M | -67.29M | -90.89M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 35.8% | 46.2% | - |
| Operating Margin % | -42,363.3% | -100,571.0% | - |
| Net Margin % | -64,242.5% | -73,864.5% | - |
| ROE % | 23.7% | -241.7% | -1,490.3% |
| ROCE % | -78.2% | -105.9% | -93.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 7.09% | 11.29M | $6.77M |
| 2 | Catalio Capital Management, LP | 3.88% | 6.17M | $3.70M |
| 3 | Vanguard Capital Management LLC | 3.83% | 6.10M | $3.66M |
| 4 | Bank of America Corporation | 3.79% | 6.03M | $3.62M |
| 5 | Pale Fire Capital SE | 3.14% | 5.00M | $3.00M |
| 6 | General Catalyst Group Management, LLC | 3.07% | 4.88M | $2.93M |
| 7 | Deer Management Co. LLC | 3.00% | 4.77M | $2.86M |
| 8 | Maverick Capital Ltd. | 2.50% | 3.97M | $2.38M |
| 9 | M28 Capital Management LP | 1.17% | 1.86M | $1.11M |
| 10 | Blackrock Inc. | 1.13% | 1.80M | $1.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GUTS
FRACTYL HEALTH, INC. (GUTS) SHAREHOLDER ALERT Bernstein - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxNUzVka25ZYTJHNVk5TFB3QWxleGRGY01CZ2NnVzhKbS1mR0oxVlZoWHZ0Nkt2M1ZqY0FQeERtMzYxNTE0RmwwNFdEZjVOWm1zNnI0TTcwU2hUNF93dmp3SGhLNWRaeTNYUnVlZWxyZ1JZTkpiam5oVjlway1MOUZyRFNKMlppREtGT1JvbX…
GUTS UPCOMING DEADLINE: SueWallSt Alerts Fractyl Health, Inc. Stockholders of Securities Class Action - Contact the Firm - Morningstar
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxNUDljRU96Sk5Wazc0OFdDSXJWN2JKTURoMC1ud19MeXBGeEVmbFdxRThyWnY2RGs3YVViMTJZM3A4Z0VMVjJDWkdyWGRhMkd1SnhwU1E1SXBfVVNEbmxqMWpOMHNfTkZ6SGxPRWIwOHBJY3luelVybU1JZ1ZjcWJoUWRNT0Q4d05fc1pOUF…
Huffman, Dexter Open Investigation into Insider Trading at Energy Fuels After Trump Guts Bears Ears - House.gov
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxOSHpzbFRXSVVudkxaWnJWTjJ3UWtqNDI2RkZ2Ri1neWpPN0VSUVRRbkNtc3VxbzNiT1czeWE4dVhLU3JtdW9xOWJPUUo5ZVNUVWc1STh1X0hBRlprX0FlMXZrbVkzNDVnY2trQnlITUpxY3BvZVFlRzFtZk8yclRfUGNBVlVpaW1JbHdTNG…
$GUTS stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNTTVHRVFwSkZUa1QtUGkyNzZWVmF1emN4dlo2c3dmek9SMDU2MlJqdXFZS1RGNW9QUnNKdUg0TTlYM2N0a2Ewc3lkSXRkYUNleWdDOWVZVHRDQUJrbUlldC1Nb1BfazFOYVNhcEN0UFk1WGc3dGxIa3RwUFRDR3JqZGpEeFdwY2JYSmhicz…
Fractyl Health (GUTS) seeks approval for 1-for-5 to 1-for-15 reverse stock split - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNTnVHSjF3UUFUMlNOUTNTc2lGQnhpbE9fckRHZ1U3S0ZzYmlZckFpeWNoOEZaNlhoUUhGMnhVVDBDYS1TRFM5RkJNMTFuZ0tSWEFpd0FJS3NqNmRyOHJxVklHb0lCQlo2azJpZ0tHMlRkS0JodE9tZEJQQm5fTXZaSUVWcXUwQjBtY29FQU…
GUTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Fractyl Health, Inc. Securities Lawsuit - Contact Levi & Korsinsky - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiqAJBVV95cUxOLVVvOGRXMDJMZHhTeWR1dDR2T0xwXzJmSWZFVW5uaUVQY21wLURWcGpSWE44bWNWd2NVbWZLdDZ2cTJBTVlEb2dtZUZ2Tm8zUGpYUHZOeDBfQWR6bjR1Y0kwOG9PU1BLTURDUkdFcldleHkwZlI1RnNNYjU1clhva09oNXBHSlpJU3prdz…
GUTS — Frequently Asked Questions
What is the current share price of Fractyl Health, Inc. (GUTS)?
As of 2026-09-19 21:16 PDT, Fractyl Health, Inc. (GUTS) trades at $0.69 on NasdaqGM. Its 52-week range is $0.39 to $2.37.
What is the market capitalisation of GUTS?
Fractyl Health, Inc. (GUTS) has a market capitalisation of $109.83M on NasdaqGM.
What is the P/E ratio of GUTS?
GUTS trades at a trailing price-to-earnings (P/E) ratio of -0.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -60.00.
Is GUTS a good stock to buy?
This page provides a data-driven analysis of Fractyl Health, Inc. (GUTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.